Summary: Professor Gustav Gaudernack will present GV1001 at international
scientific conference Friday December 7, 2007
Professor Gustav Gaudernack from Rigshospitalet-Radiumhospitalet in Oslo,
Norway will at the AACR conference ”The Role of Telomeres and Telomerase in
Cancer Research” give a scientific presentation titled “GV1001: A Universal
Cancer Vaccine Targeting Telomerase”. The presentation includes a discussion of
the many promising results from clinical trials of GV1001 in a number of cancer
indications since the mid-nineties. The presentation will be made available on
Pharmexa's homepage as soon as possible.
The AACR (American Association for Cancer Research) conference takes place in
San Francisco from December 6-9, 2007.
Hørsholm, December 3, 2007
Jakob Schmidt
Chief Executive Officer
Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45
4516 2525
Claude Mikkelsen, Vice President, Corporate Affairs and Communication,
telephone +45 4516 2525 or +45 4060 2558
Note to editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer and
chronic diseases, as well as serious infectious diseases such as HIV,
influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide
vaccine that has entered phase III trials in pancreatic cancer and phase II
trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, GENimmune, IDM Pharma and
Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs
approximately 105 people and is listed on the Copenhagen Stock Exchange under
the trading symbol PHARMX.
